Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Oct 27, 2022--
The "Age-related Macular Degeneration Market Share, Size, Trends, Industry Analysis Report, By Drugs, By Product, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global Age-related Macular Degeneration (AMD) market size is expected to reach USD 14.43 billion by 2030. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
Companies Mentioned
The AMD industry is boosted by an increase in the frequency of eye-related diseases and an increase in the number of refractive eye surgeries for eye disorders. As per the WHO, in 2019, around 2.2 billion people from across the globe have been suffering from one or the other kind of visual impairment, and out of this, 123.7 million people have uncorrected refractive errors.
The different types of refractive errors include nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia. Glasses, contact lenses, and laser eye surgery are the commonly available treatment for the correction of refractive errors. Due to the discomfort offered by wearing glasses and contact lenses, more and more people are inclined towards the adoption of refractive eye surgery to correct their refractive errors.
Furthermore, as per the American Refractive Surgery Council, in 2017, more than 29 million LASIK procedures were performed in the US. As per the American Association of Ophthalmology, in the US, 70% to 80% of people with refractive error opt for LASIK eye surgery, and 20% to 30% opt for PRK surgery. Thr intravitreal wearables segment accounted for the leading share in the market. The intravitreal segment is growing in popularity because tailored drug administration makes it more effective. In addition, the various anti-VEGF injections are given intravitreal or intraocularly. Anti-Vascular Endothelial Growth Factor medications are used to treat wet AMD (anti-VEGF).
Lucentis (ranibizumab) and Eylea (aflibercept) are two FDA-approved medications that are commonly prescribed for AMD. Avastin (bevacizumab), an off-label medication, is also widely utilized. Wet AMD is also treated with photodynamic therapy (PDT), which reduces the progression of vision impairment.
The publisher has segmented the Age-related Macular Degeneration (AMD) Market report based on product, drugs, route of administration, distribution channel, and region:
Age-related Macular Degeneration (AMD), Product Outlook (Revenue - USD Billion, 2018 - 2030)
Age-related Macular Degeneration (AMD), Drugs Outlook (Revenue - USD Billion, 2018 - 2030)
Age-related Macular Degeneration (AMD), Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)
Age-related Macular Degeneration (AMD), Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)
Age-related Macular Degeneration (AMD), Regional Outlook (Revenue - USD Billion, 2018 - 2030)
For more information about this report visit https://www.researchandmarkets.com/r/putq44
View source version on businesswire.com:https://www.businesswire.com/news/home/20221027005711/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 10/27/2022 09:44 AM/DISC: 10/27/2022 09:44 AM
http://www.businesswire.com/news/home/20221027005711/en